I order in this pharmacy is not the first time. As and range of drugs. There are rare medicines that are hard to find in other pharmacies. How to delivery fast kamagra australia Thank you for your good work.All is as it should be.
ASCO: Dr. Martine Piccart, in Karnofsky Lecture,
Outlines Vision for the Empowering of Academic
By Susan Beck | June 10, 2013Executive Editor, ONCOLOGY
CHICAGO—The David A. Karnofsky Memorial Award, ASCO’s highest scientific honor, went this year toDr. Martine J. Piccart, who is internationally recognized for her unflagging dedication and innovativeapproaches to the development of drugs and regimens that will truly make a difference in the lives of patientswith breast cancer. Dr. Piccart is a professor of oncology at the Université libre de Bruxelles, director ofmedicine at the Jules Bordet Institute (Belgium), a member of the Belgian Royal Academy of Medicine,cofounder and chair of the Breast International Group (BIG), president of the European Society for MedicalOncology (ESMO), president-elect of the European Cancer Organisation (ECCO), and a past president of theEuropean Organisation for Research and Treatment of Cancer (EORTC). She has served as the principalinvestigator or co-principal investigator on numerous landmark trials, including HERA, MINDACT, andALLTO.
Martine Piccart, MD, PhD; Photo by ASCO/Silas Crews 2013
Motivated by her mother’s battle with breast cancer, Dr. Piccart has been actively involved in breast cancerresearch for the past 30 years. In her Karnofsky Award lecture, entitled “Academic Medical ResearchWorldwide, Quo Vadis?” she enumerated lessons to be learned from the past several decades of breast cancerresearch, and outlined her vision for the shape effective research will need to take in the years to come. Tyingtogether the many ideas she set forth was her conviction that academic researchers must play the role of theguardian who ensures that patients’ needs remain the top priority in all research. She noted that, given thecurrent trend of reduction in federal funding of clinical research in the United States, what she had to saywould have increasing relevance in this country, as well as in Europe.
Dr. Piccart described the years right before her entry into medicine—the 1960s and 1970s—as the “goldenage” of academic research. The time required then to take a protocol from initial concept to the first patientwas only 3 to 9 months, and the chief focus of clinical research was on public health. These years were
followed by the “silver” and “bronze” ages, which have been characterized by the growth of bureaucracy, theincreasing involvement of regulatory bodies, limited or no government involvement (except in the UnitedStates), and more “business-oriented” trials. The time required to activate a trial protocol has expanded to 15to 36 months, and costs have also escalated tremendously—largely due, she said, to excessive andcompulsive monitoring.
To counteract these tendencies, Dr. Piccart founded the Breast International Group in 1996. With BIG, shehoped that collaboration among researchers across continents would help speed trial activation and acceleratethe development of the novel and effective treatments patients needed and wanted. Initially just active inEurope, BIG soon grew to involve academic research centers from around the world and now numbers 49member groups. BIG has run some of the most important large breast cancer trials of the past 15 years,including BIG 1-98, HERA, ALLTO, MINDACT, and APHINITY.
Dr. Piccart shared some of the important lessons she and her colleagues have learned from these large trials.
With BIG 1-98, the importance of fighting back against the pharmaceutical industry’s preference forone-size-fits-all trials became clear. In this trial, the pharmaceutical company was just interested in astraightforward comparison of the new drug (letrozole [Femara]) vs tamoxifen. The investigators, however,had other interests, including questions about the sequencing of the drugs. Ultimately, the investigatorsprevailed, and the trial went forward with four arms, including two that involved sequences of the two agents.
In HERA, the lesson learned took the form of a mistake to be avoided in the future: Underfunding oftranslational research resulted in a very slow and inefficient biomarker discovery process—and consequentlyin a missed opportunity to identify patients who were resistant to trastuzumab (Herceptin), and those whowere cured without trastuzumab.
With regard to neoadjuvant trials, Dr. Piccart noted that there are three assumptions that are commonlymade—but that they are not all, or always, valid. The first of these assumptions is that neoadjuvant trials canpredict the success of chemotherapeutic agents and endocrine agents. This assumption, she said, has provenlargely true, at least with respect to taxanes and aromatase inhibitors. The second assumption—thatneoadjuvant trials can predict the success of new targeted agents—has proven sometimes valid (as in the caseof trastuzumab) but other times not valid (as in the case of lapatinib [Tykerb] or bevacizumab [Avastin]).
However, the third assumption—that neoadjuvant trials can identify clinically useful markers—so far has notbeen borne out. There have been false-positive signals or no signals at all in biomarker research inneoadjuvant trials. In fact, Dr. Piccart noted that biomarker research to improve the tailoring of anti-HER2therapy has so far been quite disappointing.
How can the deficiencies in neoadjuvant trials be rectified? Dr. Piccart shared several lessons that BIGresearchers have learned over the years. First, she emphasized that optimal trial design requires lengthydiscussions involving all parties. Second, safety issues must be adequately addressed. And finally, it must bepossible to kill the trial “in utero” if the drug performs poorly.
The research model of the future, Dr. Piccart said, would have to be one of collaboration between academicresearchers and the pharmaceutical industry (something that may well come to be the case in the UnitedStates, as well as in Europe). In this model, the database would reside at the academic institutions, so that itmight continue to live on after the trial’s primary endpoints have been reached. Safety data would be sharedwith the pharmaceutical company right away. Efficacy data would only be seen by a statistician who does notsit on the trial’s steering committee; once endpoints have been reached, the efficacy data would be transferredto the pharmaceutical company, while continuing to live on at the academic centers.
Dr. Piccart is convinced that an “academia/pharma” hybrid model of this sort can be very successful.
Strengths of the model include its tendency to reduce commercial bias and conflicts of interest, reduced costsfor the pharmaceutical company, and considerable benefits for patients (full transparency of all results and anincreased likelihood of long-term follow-up). However, the model also has vulnerabilities. It can only be
successful, she said, if academic researchers are in the driver’s seat and exhibit strong leadership; alsoessential to its success is a willingness on the part of the pharmaceutical industry to trust the academics.
Dr. Piccart pointed out that there are numerous “burning questions” in the area of breast cancer treatment,and that the pharmaceutical industry is not particularly interested in many of these. It is only with a model inwhich academic researchers take the lead, she said, that we will have the nondrug and “cheap drug” trials thatare badly needed, that the performance of breast cancer drugs in older women will be investigated, that theneeds of women in the developing world will be addressed, and that progress will be made in the area ofmetastatic breast cancer.
Marginal annotations on the classification of plants found in Christoph Jakob Trew’s Plantae selectae (1750-1773) [Norimbergae] [Nuremberg]: s.n., 1750 (-1773). The annotations are found in copy 1 of this work. NB. Plates 101-120 form the Supplementum to Plantae Selectae (1790) Trew’s title Annotations in copy 1 Modern name if different Cedrus foliis rigidis acumina
Rabbi Akiva 1, PO Box 2707 91026 Jerusalem, Israel firstname.lastname@example.org; www.jerusalem-eternal-tours.com Conference & Tour Of Israel - April 17 to April 29, 2013 14 Day Holy Land Experience: Day 1 - Tuesday, April 16: The Journey Begins Board your flight and head to Israel. Day 2 - Wednesday, April 17: Arrival Arrive in Israel, be greeted and assisted by a Jer